预防心血管再狭窄纳米颗粒载药涂层支架的研究.docVIP

预防心血管再狭窄纳米颗粒载药涂层支架的研究 the drug-loading nanoparticle coating stent for preventing restenosis Ni zhonghua Yi Hong Wan Yuexuan Gu Xingzhong (Deptartment of Mechanical Engineering, Southeast University, Nanjing 210096, China) Abstract On the basis of comprehensively analyzing the respective advantages of drug-loading nanoparticles and stent in treating cardiovascular restenosis, this paper proposes a new scenario which integrated the drug-loading nanoparticlse with stent to make newfashioned drug-loading nanoparticles coating stent. The optimal design and experiment analysis for the stent, the choice and making for nanoparticles drug, and the mechanism and method for drug-loading nanoparticles and stent self-assembly etc. which deal with the research and development of drug-loading nanoparticles coating stent were studied. In the meantime, a new method which realized the self-assembly of drug-loading nanoparticles and stent by comprehensively applying the micro-forces such as dielectrophoretic force, capillary force, and hydrophobic force etc. was put forward, so was the self-assembly process drawing. The aforementioned research results provide the feasible scenario for the development of drug-loading nanoparticle coating stent ultimately. Keywords: drug-loading nanoparticles; stent; restenosis; nonlinear finite element theory; self-assembly 随着物质生活水平的提高，生活方式的改变，心血管狭窄引起的冠心病发病率也越来越高，已经成为危及人类生命健康安全的主要疾病之一。目前冠心病的治疗分为药物治疗、外科手术和介入治疗三大类。采用药物治疗的办法往往时间周期长、见效慢、副作用大，容易产生对药物的依赖性；外科手术则对病人产生永久性的伤害；而介入性治疗方法由于其微创伤和高效性，成为目前治疗血管狭窄引起的冠心病的一种新型方法。但是成功的经皮腔内冠状动脉成形术ngioplasty, PTCA）术后3～6个月内仍有30%～50%的再狭窄发生（血管成型术后发生的再次阻塞称为再狭窄）。预防再狭窄的发生已成为微创介入治疗心血管疾病领域引人关注的研究热点[1]。 随着人们对再狭窄发生的机理研究的不断深入，发现微创介入治疗造成血管壁损伤引发的平滑肌细胞增生、血栓形成及血管壁重塑是造成再狭窄的3个主要原因[2]。保持局部高的药物浓度和长期的药物控释是治疗前2种原因的主要方法，而植入支架术对损伤血管起支持作用，能减少血管壁重塑的影响，成为解决血管壁重塑的主要方法。于是人们自然产生了将植入支架作为药物载体，进行局部给药的方式治疗再狭窄，并制造了药物涂层支架(drug-coating stents ) 。目前已明确证实有效降低再狭窄的药物涂层支架由于支架涂药表面仅能覆盖血管内膜面的5%～12%，因而其载药量是有限的缺点，仍有10%左右的再狭窄发生。 载药纳米颗粒是纳米技术与现代医药学相结合的产物，是一种药物控释